Eli Lilly (LLY) Capital Expenditures (QoQ) (2009 - 2026)

Eli Lilly (LLY) Capital Expenditures (QoQ) (2009 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Gsk 92,316,836.42 Bn 92,316,831.46 Bn 7.76 Bn
2 Eli Lilly 983.57 Bn 978.29 Bn 16.22 Bn
3 Johnson & Johnson 553.56 Bn 531.50 Bn 15.96 Bn
4 AbbVie 383.35 Bn 374.00 Bn 10.78 Bn
5 Merck 281.71 Bn 276.06 Bn 12.09 Bn
6 Amgen 182.20 Bn 170.16 Bn 5.87 Bn
7 Gilead Sciences 153.71 Bn 145.98 Bn 5.52 Bn
8 Pfizer 143.75 Bn 130.98 Bn -1.21 Bn
9 Bristol Myers Squibb 109.71 Bn 99.25 Bn 8.07 Bn
10 Novartis Ag 108.28 Bn 107.60 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -8.67%
Dec 31, 2025 21.99%
Sep 30, 2025 23.05%
Jun 30, 2025 12.36%
Mar 31, 2025 0.92%
Dec 31, 2024 10.77%
Sep 30, 2024 10.28%
Jun 30, 2024 24.18%
Mar 31, 2024 -7.91%
Dec 31, 2023 10.38%
Sep 30, 2023 31.44%
Jun 30, 2023 10.43%
Mar 31, 2023 33.51%
Dec 31, 2022 -18.88%
Sep 30, 2022 66.36%
Jun 30, 2022 1.53%
Mar 31, 2022 25.39%
Dec 31, 2021 -13.48%
Sep 30, 2021 -11.67%
Jun 30, 2021 26.97%